Table 5.
Open in new tab

Outcomes by monogenic versus non-monogenic disease.

Monogenic [n = 17]Non-monogenic [n = 199]OR [95% CI]p-value
H=Hospitalisation15 [88.2%]139 [69.8%]3.24 [0.88, 20.95]0.12
ICU hospitalisation9 [52.9%]13 [6.5%]14.54 [4.56, 49.98]<0.001
G-tubea7 [41.2%]11 [5.5%]11.96 [3.74, 37.82]<0.001
TPN in hospital8 [47.1%]23 [11.6%]6.80 [2.35, 19.58]<0.001
TPN at home2 [11.8%]2 [1.0%]13.13 [1.49, 115.98]0.01
Surgery4 [23.5%]37 [18.6%]1.35 [0.36, 4.06]0.62
5-ASA exposure8 [47.1%]164 [82.4%]0.19 [0.07, 0.53]0.001
5-ASA failure5 [62.5%]111 [67.7%]0.92 [0.19, 6.62]0.93
Anti-TNF exposure5 [29.4%]111 [55.8%]0.33 [0.10, 0.93]0.04
Anti-TNF failure3 [60.0%]56 [50.5%]2.57 [0.32, 52.92]0.42
Weight z-score <-2 at 3-year follow-up2/9 [22.2%]9/146 [6.2%]3.00 [0.43,13.13]0.19
Height z-score <-2 at 3-year follow-up4/9 [44.4%]12/146[8.2%]5.17 [1.30, 17.60]0.01
BMI z-score <-2 at 3-year follow-up0/9 [0.0%]3/146 [2.1%]n.e.1.00
HSCT7 [41.2%]0 [0.0%]n.e.<0.001
Death2 [11.8%]0 [0.0%]n.e.0.006
Monogenic [n = 17]Non-monogenic [n = 199]OR [95% CI]p-value
H=Hospitalisation15 [88.2%]139 [69.8%]3.24 [0.88, 20.95]0.12
ICU hospitalisation9 [52.9%]13 [6.5%]14.54 [4.56, 49.98]<0.001
G-tubea7 [41.2%]11 [5.5%]11.96 [3.74, 37.82]<0.001
TPN in hospital8 [47.1%]23 [11.6%]6.80 [2.35, 19.58]<0.001
TPN at home2 [11.8%]2 [1.0%]13.13 [1.49, 115.98]0.01
Surgery4 [23.5%]37 [18.6%]1.35 [0.36, 4.06]0.62
5-ASA exposure8 [47.1%]164 [82.4%]0.19 [0.07, 0.53]0.001
5-ASA failure5 [62.5%]111 [67.7%]0.92 [0.19, 6.62]0.93
Anti-TNF exposure5 [29.4%]111 [55.8%]0.33 [0.10, 0.93]0.04
Anti-TNF failure3 [60.0%]56 [50.5%]2.57 [0.32, 52.92]0.42
Weight z-score <-2 at 3-year follow-up2/9 [22.2%]9/146 [6.2%]3.00 [0.43,13.13]0.19
Height z-score <-2 at 3-year follow-up4/9 [44.4%]12/146[8.2%]5.17 [1.30, 17.60]0.01
BMI z-score <-2 at 3-year follow-up0/9 [0.0%]3/146 [2.1%]n.e.1.00
HSCT7 [41.2%]0 [0.0%]n.e.<0.001
Death2 [11.8%]0 [0.0%]n.e.0.006

n.e. = not estimable.

Includes one patient with monogenic disease who had gastrojejunal [GJ] tube.

Table 5.
Open in new tab

Outcomes by monogenic versus non-monogenic disease.

Monogenic [n = 17]Non-monogenic [n = 199]OR [95% CI]p-value
H=Hospitalisation15 [88.2%]139 [69.8%]3.24 [0.88, 20.95]0.12
ICU hospitalisation9 [52.9%]13 [6.5%]14.54 [4.56, 49.98]<0.001
G-tubea7 [41.2%]11 [5.5%]11.96 [3.74, 37.82]<0.001
TPN in hospital8 [47.1%]23 [11.6%]6.80 [2.35, 19.58]<0.001
TPN at home2 [11.8%]2 [1.0%]13.13 [1.49, 115.98]0.01
Surgery4 [23.5%]37 [18.6%]1.35 [0.36, 4.06]0.62
5-ASA exposure8 [47.1%]164 [82.4%]0.19 [0.07, 0.53]0.001
5-ASA failure5 [62.5%]111 [67.7%]0.92 [0.19, 6.62]0.93
Anti-TNF exposure5 [29.4%]111 [55.8%]0.33 [0.10, 0.93]0.04
Anti-TNF failure3 [60.0%]56 [50.5%]2.57 [0.32, 52.92]0.42
Weight z-score <-2 at 3-year follow-up2/9 [22.2%]9/146 [6.2%]3.00 [0.43,13.13]0.19
Height z-score <-2 at 3-year follow-up4/9 [44.4%]12/146[8.2%]5.17 [1.30, 17.60]0.01
BMI z-score <-2 at 3-year follow-up0/9 [0.0%]3/146 [2.1%]n.e.1.00
HSCT7 [41.2%]0 [0.0%]n.e.<0.001
Death2 [11.8%]0 [0.0%]n.e.0.006
Monogenic [n = 17]Non-monogenic [n = 199]OR [95% CI]p-value
H=Hospitalisation15 [88.2%]139 [69.8%]3.24 [0.88, 20.95]0.12
ICU hospitalisation9 [52.9%]13 [6.5%]14.54 [4.56, 49.98]<0.001
G-tubea7 [41.2%]11 [5.5%]11.96 [3.74, 37.82]<0.001
TPN in hospital8 [47.1%]23 [11.6%]6.80 [2.35, 19.58]<0.001
TPN at home2 [11.8%]2 [1.0%]13.13 [1.49, 115.98]0.01
Surgery4 [23.5%]37 [18.6%]1.35 [0.36, 4.06]0.62
5-ASA exposure8 [47.1%]164 [82.4%]0.19 [0.07, 0.53]0.001
5-ASA failure5 [62.5%]111 [67.7%]0.92 [0.19, 6.62]0.93
Anti-TNF exposure5 [29.4%]111 [55.8%]0.33 [0.10, 0.93]0.04
Anti-TNF failure3 [60.0%]56 [50.5%]2.57 [0.32, 52.92]0.42
Weight z-score <-2 at 3-year follow-up2/9 [22.2%]9/146 [6.2%]3.00 [0.43,13.13]0.19
Height z-score <-2 at 3-year follow-up4/9 [44.4%]12/146[8.2%]5.17 [1.30, 17.60]0.01
BMI z-score <-2 at 3-year follow-up0/9 [0.0%]3/146 [2.1%]n.e.1.00
HSCT7 [41.2%]0 [0.0%]n.e.<0.001
Death2 [11.8%]0 [0.0%]n.e.0.006

n.e. = not estimable.

Includes one patient with monogenic disease who had gastrojejunal [GJ] tube.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close